Total Revenue: Approximately $555 million for Q1 2025. Cabozantinib Franchise Net Product Revenue: $513.3 million for Q1 2025. CABOMETYX Net Product Revenue: $510.9 million, including $12 million in clinical trial sales. Gross to Net for Cabozantinib Franchise: 28.9% in Q1 2025. Operating Expenses: Approximately $369 million for Q1 2025. GAAP Net Income: Approximately $159.6 million or $0.57 per share basic and $0.55 per share diluted. Non-GAAP Net Income: Approximately $179.6 million or $0.64 per share basic and $0.62 per share diluted. Cash and Marketable Securities: Approximately $1.65 billion as of March 31, 2025. Share Repurchase: Approximately $289 million worth of shares repurchased, retiring approximately 8 million shares at an average price of $35.83 per share. 2025 Full Year Revenue Guidance: Increased to $2.05 billion to $2.15 billion for net product revenue and $2.25 billion to $2.35 billion for total revenue.

Warning! GuruFocus has detected 5 Warning Sign with EXEL.

Release Date: May 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Exelixis Inc (NASDAQ:EXEL) reported a strong first quarter with significant progress across all business components. The US cabo franchise saw a 36% year-over-year growth in net product revenues, reaching $513 million. Exelixis Inc (NASDAQ:EXEL) received US regulatory approval for CABOMETYX in neuroendocrine tumors ahead of schedule. The company increased its 2025 full-year financial guidance for net product revenues and total revenues by $100 million. Exelixis Inc (NASDAQ:EXEL) is advancing new molecules from its pipeline, with Zanza expected to be a key oncology franchise opportunity in 2025.

Negative Points

Gross to net deductions increased in the first quarter of 2025 due to higher PHS and 340B volumes. The company experienced little inventory destocking, which could impact future inventory management. Exelixis Inc (NASDAQ:EXEL) faces risks related to product commercial success, market competition, and regulatory review processes. The development program for XL495 was discontinued due to drug-related toxicities. There is uncertainty regarding the early trajectory and stabilization of the neuroendocrine tumor launch.

Q & A Highlights

Q: Could you help us understand what's been driving cabozantinib growth, and provide some color on the launch in neuroendocrine tumors? A: The growth is primarily driven by renal cell carcinoma (RCC), particularly frontline RCC with the cabo/nivo combination. The CheckMate 9ER 5-year follow-up data has resonated well with physicians. Regarding neuroendocrine tumors (NET), there was some utilization before approval, but the launch is in early days. Feedback from prescribers is positive, and the team is actively promoting the drug.

Story Continues

Q: Did you see a bolus effect in the early days of the NET launch, and when do you expect it to stabilize? A: We don't expect a bolus effect due to the advanced stage of disease in NET patients. There is significant prescriber excitement, and we are seeing new prescriptions. We will continue to monitor trends as the launch progresses.

Q: Can you provide context on the seasonality for cabozantinib this year? A: The seasonality seen in past years is gone due to our specified small manufacturer designation, which stabilizes gross to net across the year. We project gross to net to be in the 29% to 30% range, and there were no significant inventory dynamics this year.

Q: Regarding the full year's 2025 guidance increase, how much of it comes from NET? A: The majority of the guidance increase is driven by the RCC-based business, with a smaller contribution from NET. We are tracking the momentum closely and will update guidance when we have more confidence.

Q: How does the current environment influence your business development plans? A: We are open for business development, focusing on high-conviction assets within GU and GI oncology. We aim to convert differentiating clinical data into commercial success, similar to the cabo story. We are not looking to buy on the cheap but are focused on high science and moving the needle for patients.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments